- Details
- Alicia Morgans and Nima Sharifi discuss the role of the HSD3B1 gene and its variants in prostate cancer. Dr. Sharifi explains that the adrenal permissive allele of HSD3B1 is common in people of European ancestry and is associated with increased conversion of adrenal androgen precursors to potent androgens like DHT. This allele is linked to faster progression and higher prostate cancer-specific mor...
|
- Details
- Zach Klaassen and Neal Shore discuss the outcomes of the EMBARK trial, focusing on treatment strategies for high-risk biochemically recurrent prostate cancer. In this detailed conversation, Dr. Shore explains the trial’s structure, which tested the efficacy of enzalutamide combined with leuprolide acetate or as monotherapy. Trial findings reveal a significant improvement in metastasis-free surviva...
|
- Details
- Rana McKay discusses the NePtune study, investigating PARP inhibitors as a neoadjuvant treatment for prostate cancer patients with BRCA1/2 mutations. This study, inspired by the success of PARP inhibitors in metastatic settings and neoadjuvant successes in other cancers, aims to address the aggressive nature of BRCA-mutated prostate cancer earlier in the disease course. With a multi-institutional...
|
- Details
- Edwin Posadas delves into the complexities and aspirations of the STEEL RTOG 3506 trial, a study initiated as a follow-up to the RTOG 9601 trial's insights into androgen ablation's role in improving outcomes for men undergoing salvage radiation therapy post-biochemical relapse. The STEEL trial, aiming to harness more intensive AR blockade techniques available in modern medicine, embarked on explor...
|
- Details
- Sam Chang hosts a conversation with Mark Preston discussing innovative chemotherapy combinations for non-muscle invasive bladder cancer. Drawing inspiration from Dr. Mike O'Donnell's work with gemcitabine and docetaxel, Dr. Preston's team sought to replicate these promising results. Their multi-institutional retrospective analysis examined over 100 patients treated with this regimen after BCG ther...
|
- Details
- Alicia Morgans interviews Alan Bryce about his session on radiopharmaceutical therapies for mCRPC with bone metastases, focusing on the decision-making between radium-223 and lutetium-177. Dr. Bryce explains the session aimed at practical clinical decision-making, emphasizing the underlying science of radiopharmaceuticals, including the distinctions between alpha and beta emitters and their target...
|
- Details
- Dan George discusses the CheckMate-67T study with Saby George, a phase three trial comparing intravenous and subcutaneous administration of nivolumab in treatment-refractory kidney cancer patients. Conducted across 73 centers in 17 countries, this trial aimed to assess if subcutaneous nivolumab could match the systemic effects of its IV counterpart. Meeting its co-primary pharmacokinetic endpoints...
|
- Details
- Pedro Barata and Nizar Tannir delve into the eight-year results of the CheckMate-214 trial, showcasing the sustained efficacy of ipilimumab and nivolumab (ipi/nivo) in advanced renal cell carcinoma (RCC). Dr. Tannir highlights the treatment's enduring hazard ratio and significant mortality risk reduction, emphasizing the notable longevity and durability of patient responses. Their conversation nav...
|
- Details
- Sam Chang converses with Neal Shore about the KEYNOTE-676 trial, focusing on combining pembrolizumab with BCG for high-risk NMIBC patients previously treated with BCG. This study aims to explore the potential synergy between two immunotherapeutic agents, leveraging pembrolizumab's success in MIBC to improve outcomes in NMIBC. With enrollment progressing well, the trial signals a collaborative futu...
|
- Details
- Zach Klaassen discusses the ARAMON trial with Andrew Laccetti, which focuses on the impact of enzalutamide and darolutamide on testosterone levels in patients with high-risk nonmetastatic hormone-sensitive prostate cancer. Dr. Laccetti emphasizes the critical need for treatments that not only enhance cancer outcomes but also minimize side effects and improve quality of life for men undergoing long...
|
